microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2010-2(104)-74-77microbe-531Research ArticleПАТОГЕНЕЗ И ИММУНОПРОФИЛАКТИКАPATHOGENESIS AND IMMUNOPROPHYLAXISДНК-иммунизация против бешенстваAntirabies DNA ImmunizationТучковИ. В.TuchkovI. V.microbe@san.ruНикифоровА. К.NikiforovA. K.noemail@neicon.ruРоссийский научно-исследовательский противочумный институт «Микроб»РоссияRussian Research Anti-Plague Institute MicrobeRussian Federation20102004201002(104)7477Copyright © Тучков И.В., Никифоров А.К., 20102010Тучков И.В., Никифоров А.К.Tuchkov I.V., Nikiforov A.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/531

В обзоре приводятся литературные данные, посвященные разработке ДНК-вакцин против вируса бешенства. Представлены результаты исследований, касающиеся генной вакцинации различных моделей лабораторных животных и разных путей введения вакцины. Рассматривается возможность потенцирования иммуногенности ДНК-вакцин при использовании адъювантов и цитокинов. Обсуждаются пути совершенствования полинуклеотидных вакцин.

Cited are literary data related to the development of DNA vaccines against rabies virus. Research results regarding gene vaccination of different models of laboratory animals and different ways of vaccine introduction are presented. Possibility to potentiate immunogenicity of DNA vaccines using adjuvants and cytokines is considered. Ways of improving of polynucleotide vaccines are discussed.

бешенствоДНК-вакциныполинуклеотидные вакциныrabiesDNA vaccinespolynucleotide vaccinesReferencesО санитарно-эпидемиологической обстановке в Российской Федерации в 2008 году: Государственный доклад. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора. 2009. 467 с.О санитарно-эпидемиологической обстановке в Российской Федерации в 2008 году: Государственный доклад. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора. 2009. 467 с.Супотницкий М.В. ДНК-иммунизация в профилактике инфекционных болезней сельскохозяйственных животных. Ветеринария. 1998; 5:18-24Супотницкий М.В. ДНК-иммунизация в профилактике инфекционных болезней сельскохозяйственных животных. Ветеринария. 1998; 5:18-24Biswas S., Reddy G. S., Srinivasan V.A., Rangarajan P.N. Pre-exposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum. Gene Ther. 2001; 12:1917-22.Biswas S., Reddy G. S., Srinivasan V.A., Rangarajan P.N. Pre-exposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum. Gene Ther. 2001; 12:1917-22.Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics. Current Clinical Developments. Mol. Ther. 2009; 17(4):585-92.Bodles-Brakhop A.M., Heller R., Draghia-Akli R. Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics. Current Clinical Developments. Mol. Ther. 2009; 17(4):585-92.Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E. et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998; 351(9112):1320-5.Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E. et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998; 351(9112):1320-5.Ceberea I., Dorrella L., McShaneb H., Simmonsa A., McCormackc S., Schmidtd C. et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine. 2006; 24(4):417-25.Ceberea I., Dorrella L., McShaneb H., Simmonsa A., McCormackc S., Schmidtd C. et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine. 2006; 24(4):417-25.Cox J.H., Dietzschold B., Schneider L.G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun. 1977; 16(3):754-9.Cox J.H., Dietzschold B., Schneider L.G. Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun. 1977; 16(3):754-9.Diogo M.M., Ribeiro S.C., Queiroz J.A. et al. Production, purification and analysis of an experimental DNA vaccine against rabies. J. Gene Med. 2001; 3:577-84.Diogo M.M., Ribeiro S.C., Queiroz J.A. et al. Production, purification and analysis of an experimental DNA vaccine against rabies. J. Gene Med. 2001; 3:577-84.Ertl H., Verma P., Xiang Z. Plasmid vectors as anti-viral vaccines. DNA vaccines: A new era in vaccinology. Ann. NY Acad. Sci. 1995; 772:77-87.Ertl H., Verma P., Xiang Z. Plasmid vectors as anti-viral vaccines. DNA vaccines: A new era in vaccinology. Ann. NY Acad. Sci. 1995; 772:77-87.Ertl H., Xiang Z. DNA vaccines to rabies virus: Effects of cytokines on the immune response. In: Vaccine 96: Molecular Approaches to the Control of Infectious Diseases. New York: Cold Spring Harbor Laboratory Press; 1996. 83-6.Ertl H., Xiang Z. DNA vaccines to rabies virus: Effects of cytokines on the immune response. In: Vaccine 96: Molecular Approaches to the Control of Infectious Diseases. New York: Cold Spring Harbor Laboratory Press; 1996. 83-6.Fischer L., Minke J., Dufay N., Baudu P., Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine. 2003; 21(31):4593-6.Fischer L., Minke J., Dufay N., Baudu P., Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine. 2003; 21(31):4593-6.Fodor I., Kucsera L., Fodor N., Palfi V., Grabko V.I. Gene immunization of mice with plasmid DNA expressing rabies virus glycoprotein. Acta Vet. Hung. 2000; 48(2):229-36.Fodor I., Kucsera L., Fodor N., Palfi V., Grabko V.I. Gene immunization of mice with plasmid DNA expressing rabies virus glycoprotein. Acta Vet. Hung. 2000; 48(2):229-36.Hua R.L., Liua Y., Zhang S.F., Zhang F., Fooks A.R. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine. 2007; 25(29):53017.Hua R.L., Liua Y., Zhang S.F., Zhang F., Fooks A.R. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine. 2007; 25(29):53017.Jallet C., Jacob Y., Bahloul C., Drings A., Desmezieres E., Tordo N., Perrin P. Chimeric lyssavirus glycoproteins with increased immunological potential. J. Virol. 1999; 73(1):225-33.Jallet C., Jacob Y., Bahloul C., Drings A., Desmezieres E., Tordo N., Perrin P. Chimeric lyssavirus glycoproteins with increased immunological potential. J. Virol. 1999; 73(1):225-33.Lodmell D.L., Ewalt L.C. Post-exposure DNA vaccination protects mise against rabies virus. Vaccine 2001; 19:2468-73.Lodmell D.L., Ewalt L.C. Post-exposure DNA vaccination protects mise against rabies virus. Vaccine 2001; 19:2468-73.Lodmell D.L., Ewalt L.C. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine. 2000; 18(22):2394-8.Lodmell D.L., Ewalt L.C. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine. 2000; 18(22):2394-8.Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., Hanlon C.A. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine. 2001; 20(5-6):838-44.Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., Hanlon C.A. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine. 2001; 20(5-6):838-44.Lodmell D.L., Ray N.B., Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine. 1998; 16:115-8.Lodmell D.L., Ray N.B., Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine. 1998; 16:115-8.Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H. et al. DNA immunization protects non-human primates against rabies virus. Nat. Med. 1998; 4:949-79.Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H. et al. DNA immunization protects non-human primates against rabies virus. Nat. Med. 1998; 4:949-79.Lodmell D.L., Ray N.B., Ulrich T., Ewalt L.C. DNA vaccination of mice against rabies virus: effects of the route of administration and the adjuvant monophosphoryl lipid A (MPL). Vaccine. 2000; 18 (11):1059-66.Lodmell D.L., Ray N.B., Ulrich T., Ewalt L.C. DNA vaccination of mice against rabies virus: effects of the route of administration and the adjuvant monophosphoryl lipid A (MPL). Vaccine. 2000; 18 (11):1059-66.Lunn D.P., Soboll G., Schram B.R. et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine. 1999; 17:2245-58.Lunn D.P., Soboll G., Schram B.R. et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine. 1999; 17:2245-58.MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L. et al. First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responses. J. Infect. Dis. 1998; 178(1):92-100.MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L. et al. First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responses. J. Infect. Dis. 1998; 178(1):92-100.Margalith M., Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet. Vaccines Ther. 2006; 4(2):1-6.Margalith M., Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet. Vaccines Ther. 2006; 4(2):1-6.Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C. et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses. 2006; 22(7):678-83.Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C. et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses. 2006; 22(7):678-83.Oh Y.K., Kim J.P., Hwang T.S., Ko J.J., Kim J.M., Yang J.S., Kim C.K. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine. 2001; 19:4519-25.Oh Y.K., Kim J.P., Hwang T.S., Ko J.J., Kim J.M., Yang J.S., Kim C.K. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine. 2001; 19:4519-25.Osorio J.E., Tomlinson C.C., Frank R.S. et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17:1109-16.Osorio J.E., Tomlinson C.C., Frank R.S. et al. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17:1109-16.Perrin P., Jacob Y., Aguilar-Setien A. et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine. 1999; 18:479-86.Perrin P., Jacob Y., Aguilar-Setien A. et al. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine. 1999; 18:479-86.Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine. 1997; 15:892-5.Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine. 1997; 15:892-5.Rupprecht C., Hanlon C.A., Hemachuda T. Rabies re-examined. Lancet Infect Dis. 2002; 2(6):327-43.Rupprecht C., Hanlon C.A., Hemachuda T. Rabies re-examined. Lancet Infect Dis. 2002; 2(6):327-43.Rupprecht C., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H. et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA. 1986; 83(20):7947-50.Rupprecht C., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H. et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA. 1986; 83(20):7947-50.Smith J.S., Seidel H.D. Rabies: a new look at an old disease. Prog. Med. Virol. 1993; 40:82-106.Smith J.S., Seidel H.D. Rabies: a new look at an old disease. Prog. Med. Virol. 1993; 40:82-106.Tang D. C., DeVit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356:152-4.Tang D. C., DeVit M., Johnston S. A. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356:152-4.Ulmer J. B., Donnelly J. J., Parker S. E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259:1745-9.Ulmer J. B., Donnelly J. J., Parker S. E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259:1745-9.Wang R., Doolan D.L., Le T.P., HedstromR.C., Coonan K.M., Charoenvit Y. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998; 282(5388):476-80.Wang R., Doolan D.L., Le T.P., HedstromR.C., Coonan K.M., Charoenvit Y. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998; 282(5388):476-80.Wang Y., Xiang Z., Pasquini S., Ertl H.C. Immune response to neonatal genetic immunization. Virology. 1997; 228(2):278-84.Wang Y., Xiang Z., Pasquini S., Ertl H.C. Immune response to neonatal genetic immunization. Virology. 1997; 228(2):278-84.Wolff J. A., Malone R. W., Williams P. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247:1465-8.Wolff J. A., Malone R. W., Williams P. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247:1465-8.World survey of rabies: No. 32 for the year 1996. Geneva: World Health Organization; 1998. (WHO/EMC/ZDI/98.4).World survey of rabies: No. 32 for the year 1996. Geneva: World Health Organization; 1998. (WHO/EMC/ZDI/98.4).Xiang Z.Q., Pasquini S., Ertl H.C. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J. Immunol. 1999; 162:6716-23.Xiang Z.Q., Pasquini S., Ertl H.C. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J. Immunol. 1999; 162:6716-23.Xiang Z.Q., Spitalnik S., Tran M. et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994; 199:132-40.Xiang Z.Q., Spitalnik S., Tran M. et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994; 199:132-40.Xiang Z.Q., Spitalnik S.L., Cheng J., Erikson J., Wojczyk B., Ertl H.C.J. Immune response to nucleic acid vaccines to rabies virus. Virology. 1995; 209:569-79.Xiang Z.Q., Spitalnik S.L., Cheng J., Erikson J., Wojczyk B., Ertl H.C.J. Immune response to nucleic acid vaccines to rabies virus. Virology. 1995; 209:569-79.

The authors declare that there are no conflicts of interest present.